Actinium’s Phase 3 SIERRA data awarded Abstract of the Year by SNMMI meeting

Actinium Pharmaceuticals announced that the Society of Nuclear Medicine and Molecular Imaging, SNMMI, 2023 Annual Meeting selected Abstract 685 titled “Individualized dosing for high-dose targeted radiation of hematopoietic cells with Iomab-B prior to HCT in relapsed/refractory acute myeloid leukemia: Safety and efficacy results from the pivotal phase 3 SIERRA trial” as the Abstract of the Year. “It is a great honor for this SIERRA data abstract and this team of esteemed abstract authors to have received this award highlighting Iomab-B’s potential for people with relapsed and refractory AML,” said Sandesh Seth, Chairman and Chief Executive Officer. “Today’s SNMMI honor represents the fourth oral presentation of the SIERRA trial data at prestigious medical conferences in 2023, including TCT, EBMT, and EHA. The extensive global recognition of the SIERRA results highlights Iomab-B’s potential to transform outcomes for the significant number of people with relapsed or refractory AML by enabling increased access to bone marrow transplant via a targeted radiotherapeutic. We are committed to file our BLA submission with U.S. Food and Drug Administration in the second half of this year in our endeavor to bring this new radiotherapeutic to people with great need.”